Skip to main content
    M

    MoonLake Immunotherapeutics (MLTX)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $11.73
    -0.77 (-6.16%)

    Market Cap: $1.06B

    Last updated: Nov 17, 2026 at 11:06 AM ET

    MoonLake Immunotherapeutics (MLTX) Stock Forecast

    Updated Nov 17, 2026. Estimates and ratings come from consensus analyst data.

    Analysts expect MoonLake Immunotherapeutics (MLTX) to earn -$3.58 per share in the fiscal year ending Dec 31, 2026. Of 15 analysts, 11 rate the stock Buy or Strong Buy, 2 Hold and 2 Sell or Strong Sell, for a consensus of Buy. For the fiscal year ending Dec 31, 2027, the EPS consensus is -$3.40.

    Analyst Ratings

    Scoring Strong Buy as 1 and Strong Sell as 5, the 15 ratings average 2.33, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 73% of the ratings.

    RatingAnalystsShare
    Strong Buy16.7%
    Buy1066.7%
    Hold213.3%
    Sell213.3%
    Strong Sell00.0%
    Consensus
    Buy
    Total analysts
    15

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    Annual Estimates

    From the first fiscal year below to the second, the EPS consensus shows a smaller loss.

    Fiscal year ending Dec 31, 2026
    -$3.58
    EPS consensus
    Fiscal year ending Dec 31, 2027
    -$3.40
    EPS consensus, revenue $19.18M
    Next report
    Feb 22, 2027
    Estimated

    EPS range

    Fiscal year endingEPS consensusEPS rangeEPS analystsRevenue consensusRevenue rangeRev. analysts
    Dec 31, 2026-$3.58-$3.69 to -$3.158N/AN/A13
    Dec 31, 2027-$3.40-$4.11 to -$2.739$19.18MN/A13

    Quarterly Estimates

    The EPS consensus falls from -$0.84 for the quarter ending Dec 31, 2026 to -$0.94 for the quarter ending Mar 31, 2027.

    EPS range

    Quarter endingEPS consensusEPS rangeEPS analystsRevenue consensusRevenue rangeRev. analysts
    Dec 31, 2026-$0.84-$0.99 to -$0.6915N/AN/A14
    Mar 31, 2027-$0.94-$1.18 to -$0.793$74750N/A8

    Estimate Revisions

    Across the 2 periods below, the last 30 days brought 6 upward and 1 downward EPS revisions. Raises outnumber cuts in every period.

    PeriodUp 30 daysDown 30 days
    Fiscal year ending Dec 31, 202751
    Quarter ending Mar 31, 202710

    EPS Trend

    Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has worsened from -$3.36.

    PeriodNow7 days ago30 days ago60 days ago90 days agoChange
    Fiscal year ending Dec 31, 2026-$3.58-$3.38-$3.38-$3.38-$3.36N/A
    Fiscal year ending Dec 31, 2027-$3.40-$3.33-$3.33-$3.33-$3.33N/A
    Quarter ending Mar 31, 2027-$0.94-$1.03-$1.03-$1.03-$0.87N/A

    Frequently Asked Questions About MLTX

    What is the MLTX stock forecast?

    Consensus analyst estimates put MoonLake Immunotherapeutics's EPS at -$3.58 for the fiscal year ending Dec 31, 2026. The consensus rating from 15 analysts is Buy.

    How do analysts rate MLTX stock?

    Of 15 analysts covering MoonLake Immunotherapeutics, 1 rates it Strong Buy, 10 Buy, 2 Hold, 2 Sell and 0 Strong Sell, for a consensus of Buy.

    What EPS do analysts expect from MLTX next year?

    For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is -$3.58, with estimates from -$3.69 to -$3.15 from 8 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is -$3.40, with estimates from -$4.11 to -$2.73 from 9 analysts.

    What revenue do analysts expect from MoonLake Immunotherapeutics next year?

    For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $19.18M.

    How many analysts cover MLTX?

    15 analysts rate MoonLake Immunotherapeutics stock, and 8 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.